Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03456908 · ClinicalTrials.gov registry record · Phase 1
F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral Therapies
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03456908: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT03456908 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03456908, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The goal of this proposal is to perform first-in-man evaluation of the imaging probe F-18 tetrafluoroborate (BF4) as a PET imaging biomarker for expression of the human sodium/iodide symporter (hNIS) in tissues. .
Primary Outcome
This is a preliminary study and all analyses will be exploratory in nature.
Interventions
- COMBINATION_PRODUCT 18F-TFB-PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-03-16 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 1 |
What the finished NCT03456908 record still lists
NCT03456908 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which 18F-TFB-PET is the first listed.
NCT03456908 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03456908 about?
NCT03456908 is a clinical study titled "F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral Therapies". The goal of this proposal is to perform first-in-man evaluation of the imaging probe F-18 tetrafluoroborate (BF4) as a PET imaging biomarker for expression of the human sodium/iodide symporter (hNIS) in tissues. .
What is the current status of trial NCT03456908?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2018-03-16. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03456908?
The interventions under investigation include: 18F-TFB-PET (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03456908?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03456908's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI